Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Saswata Dutt"'
Autor:
Florence O. Bada, Evaezi Okpokoro, Nick Blok, Emmanuel Meribole, Saswata Dutt, Patrick Dakum, Alash’le Abimiku, Alice Zwerling, Sandra V. Kik
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalizati
Externí odkaz:
https://doaj.org/article/3bbb264b2e2c4e619f0f6304ce6c6447
Autor:
Florence O. Bada, Nick Blok, Evaezi Okpokoro, Saswata Dutt, Christopher Akolo, Patrick Dakum, Alash’le Abimiku
Publikováno v:
PLoS ONE, Vol 16, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/83610cb42e904522bae86e2c4b286a7a
Autor:
Fadimatu Yunusa, MPH, Maryam Bello, BSc, Gbenga A Kayode, PhD, Adeoye Adegboye, MPH, Geraldine Abone, MBBS, Fati Murtala-Ibrahim, B Pharm, Martha Okposo, MSc, Atinuke Anjorin, MBBS, Saswata Dutt, MBBS, Oche Yusuf, MHM, Nadia Sam-Agudu, Patrick Dakum, MPH
Publikováno v:
The Lancet Global Health, Vol 8, Iss , Pp S37- (2020)
Background: Tuberculosis is a main cause of death in people living with HIV and results in around 39 000 deaths every year in Nigeria. Isoniazid preventive therapy (IPT), the standard tuberculosis preventive therapy used in Nigeria, has been shown to
Externí odkaz:
https://doaj.org/article/13839da24bfb407db5dab23fd676c197
Autor:
Florence O Bada, Nick Blok, Evaezi Okpokoro, Saswata Dutt, Christopher Akolo, Patrick Dakum, Alash'le Abimiku
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0241065 (2020)
BackgroundGlobally, drug resistant tuberculosis (DR-TB) continues to be a public health threat. Nigeria, which accounts for a significant proportion of the global burden of rifampicin/multi-drug resistant-TB (RR/MDR-TB) had a funding gap of $168 mill
Externí odkaz:
https://doaj.org/article/c9ffcdf2c63b44c987c86273f050e381
Autor:
Yohanna Kambai Avong, Bolajoko Jatau, Ritmwa Gurumnaan, Nanfwang Danat, James Okuma, Istifanus Usman, Dennis Mordi, Blessing Ukpabi, Gbenga Ayodele Kayode, Saswata Dutt, Osman El-Tayeb, Bamgboye Afolabi, Isah Ambrose, Oche Agbaji, Adeline Osakwe, Ali Ibrahim, Comfort Ogar, Helga Nosiri, Eunice B Avong, Victor Adekanmbi, Olalekan Uthman, Alash'le Abimiku, Yetunde O Oni, Charles Olalekan Mensah, Patrick Dakum, Kamau Edward Mberu, Olumide A T Ogundahunsi
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0200810 (2018)
BACKGROUND:Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide. The prompt reporting of suspected ADRs to regulatory authorities to activate drug safety surveillance and regulation appears to be the most pragmatic
Externí odkaz:
https://doaj.org/article/514eef0042c34f409447ad6c5468c3ba
Autor:
Adeoye Adegboye, Gbenga A. Kayode, Saswata Dutt, Geraldine Abone, Oche Baba Yusuf, Nadia A. Sam-Agudu, Fati Murtala-Ibrahim, Fadimatu Yunusa, Maryam Bello, Patrick Dakum, Atinuke Anjorin, Martha Okposo
Publikováno v:
The Lancet Global Health, Vol 8, Iss, Pp S37-(2020)
Background Tuberculosis is a main cause of death in people living with HIV and results in around 39 000 deaths every year in Nigeria. Isoniazid preventive therapy (IPT), the standard tuberculosis preventive therapy used in Nigeria, has been shown to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508f127bcdb05a7874a20433bcff28ff
http://www.sciencedirect.com/science/article/pii/S2214109X20301789
http://www.sciencedirect.com/science/article/pii/S2214109X20301789
Autor:
B Odume, S Pals, Dennis Onotu, Ishani Pathmanathan, O Obinna, J Okuma, Saswata Dutt, Patrick Dakum, E Ekong, D Anand, Evaezi Okpokoro, N Chukwurah, H Tomlinson, K Dokubo
Publikováno v:
Universal journal of public health
Background: Nigeria has a high burden of HIV and tuberculosis (TB). To reduce TB-associated morbidity and mortality, the World Health Organization recommends that HIV-positive TB patients receive antiretroviral therapy (ART) within eight weeks of TB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcf8fbbdf1588e17174e084e382a70de
https://doi.org/10.13189/ujph.2017.050507
https://doi.org/10.13189/ujph.2017.050507
Autor:
Sandra V. Kik, Patrick Dakum, Alice Zwerling, Nick Blok, Evaezi Okpokoro, Florence Bada, Emmanuel Meribole, Saswata Dutt, Alash'le Abimiku
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-10 (2019)
BMC infectious diseases, 19(1):41. BioMed Central
BMC Infectious Diseases
BMC infectious diseases, 19(1):41. BioMed Central
BMC Infectious Diseases
Background Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb4e21d9ce1bc84c97873e2cd3614ce
https://doi.org/10.1186/s12879-018-3636-1
https://doi.org/10.1186/s12879-018-3636-1
Autor:
Alash'le Abimiku, Christopher Akolo, Evaezi Okpokoro, Saswata Dutt, Nick Blok, Patrick Dakum, Florence O Bada
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 12, p e0241065 (2020)
PLoS ONE, Vol 15, Iss 12, p e0241065 (2020)
Background Globally, drug resistant tuberculosis (DR-TB) continues to be a public health threat. Nigeria, which accounts for a significant proportion of the global burden of rifampicin/multi-drug resistant-TB (RR/MDR-TB) had a funding gap of $168 mil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b507ca05466416ff9b52778d6bfc04c
https://doi.org/10.1371/journal.pone.0241065
https://doi.org/10.1371/journal.pone.0241065
Autor:
Isah Ambrose, Olumide Ogundahunsi, Charles Mensah, Blessing Ukpabi, Olalekan A. Uthman, Alash'le Abimiku, Yohanna Kambai Avong, Patrick Dakum, Osman El-Tayeb, Adeline Osakwe, Oche Agbaji, Comfort Kunak Ogar, Yetunde Oni, Kamau Edward Mberu, Eunice Bosede Avong, Dennis Mordi, Saswata Dutt, Bolajoko Jatau, Victor Adekanmbi, Istifanus Usman, Ali Ibrahim, Ritmwa Gurumnaan, Gbenga A. Kayode, James Okuma, B. M. Afolabi, Helga Nosiri, Nanfwang Danat
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 8, p e0200810 (2018)
PLoS ONE, Vol 13, Iss 8, p e0200810 (2018)
Background\ud \ud Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide. The prompt reporting of suspected ADRs to regulatory authorities to activate drug safety surveillance and regulation appears to be the most pra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0ab4ed662a3560ddc0e5cb7f408179
https://pubmed.ncbi.nlm.nih.gov/30133453
https://pubmed.ncbi.nlm.nih.gov/30133453